Korro Bio (KRRO) vs Entrada Therapeutics (TRDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 93.9% versus a loss of 57.0%. Over five years, TRDA leads with a -85.0% price change compared with -95.7% for KRRO. Entrada Therapeutics is the larger company by market cap ($170.3 million vs $167.2 million), about 1.0 times the size, while Korro Bio is growing revenue faster (+181.5% vs -87.9%).
Entrada Therapeutics converts more of its revenue into profit, with a net margin of -565.5% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | TRDA |
|---|---|---|
| Share price | $12.18 | $4.35 |
| Market cap | $167.18M | $170.30M |
| 1-day change | -0.08% | -6.25% |
| YTD return | +52.06% | -57.68% |
| 1-year return | +93.95% | -56.97% |
| 5-year return | -95.67% | -84.95% |
| EPS (TTM) | $-8.89 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.39M | $25.42M |
| Revenue growth (YoY) | +181.46% | -87.94% |
| Net income (latest FY) | $-117.26M | $-143.75M |
| Operating margin | -1906.37% | -621.13% |
| Net margin | -1834.48% | -565.48% |
| 52-week high | $17.35 | $16.45 |
| 52-week low | $5.20 | $4.11 |
| Distance from 52-week high | -29.81% | -73.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +76.52% | +308.05% |
| Average volume | 186.03K | 401.15K |
| Shares outstanding | 13.73M | 39.15M |
| Employees | 58 | 152 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed TRDA by 150.9 percentage points over the past year.
- Entrada Therapeutics is more profitable, keeping -565.5 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
- Korro Bio grew revenue faster in its latest fiscal year (+181.46% vs -87.94%).
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Entrada Therapeutics
TRDA stock →Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees
KRRO vs TRDA FAQ
Which is bigger, Korro Bio or Entrada Therapeutics?
Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.30M compared with $167.18M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or TRDA?
KRRO returned +93.95% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and Entrada Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.